Agios: Novo's Sickle Cell Win Changes The PK Activator Game (Rating Downgrade) [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
Novo Nordisk's PK activator looks better than AGIO's mitapivat in sickle cell disease, meeting both co-primary endpoints and intensifying competitive pressure. Aqvesme's thalassemia approval is hampered by a boxed warning and REMS, limiting commercial potential to a peak of $200M in annual sales. AGIO's valuation now hinges on pipeline assets, especially tebapivat in low-risk MDS, but near-term prospects are weak and cash burn remains high. MicroStockHub/iStock via Getty Images Agios Pharmaceuticals Overview Agios Pharmaceuticals ( AGIO ) is a commercial stage biopharma that specializes in PK activation. It actually has one drug that's FDA approved for PK deficiency, branded as Pyrukynd (mitapivat). However, as I've This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. Fina
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- UnitedHealth flags challenges in Medicare obesity drug pilot [Yahoo! Finance]Yahoo! Finance
- A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly [Yahoo! Finance]Yahoo! Finance
- A Monthly Weight Loss Shot? Why Pfizer Could Topple Lilly's and Novo's GLP-1 Duopoly [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Eli Lilly hedges for a GLP-1 revenue drop-off with $7B acquisition [Yahoo! Finance]Yahoo! Finance
- Here's Why Agios Pharmaceuticals Crashed 23% Today [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 4/20/26 - Form 6-K
- 4/20/26 - Form 6-K
- 4/13/26 - Form 6-K
- NVO's page on the SEC website